Sight Sciences (SGHT)
Develops interventional devices for glaucoma surgery and dry eye treatment.
Something off on this page? Send us feedback.
Sells OMNI and SION devices for interventional glaucoma and TearCare for evaporative dry eye. Revenue is concentrated in the United States and mainly comes from glaucoma products sold to hospitals, medical centers, and eyecare professionals.
Built around interventional ophthalmic procedures, the business sells OMNI products, including OMNI Edge and Ergo Series systems, plus the SION Surgical Instrument for glaucoma procedures. TearCare and related components address evaporative dry eye linked to meibomian gland dysfunction.
Sales are concentrated in the United States, primarily through representatives and distributors serving hospitals, medical centers, and eyecare professionals. The commercial base is anchored by glaucoma products, while dry eye remains tied to broader reimbursement and market-access work.
Execution depends on physician training, practice patterns, patient selection, and payer coverage for the relevant procedures. Competition includes other MIGS products and dry-eye treatment systems, so adoption is shaped by clinical workflow, reimbursement timing, and new product activity.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 28, 2026 | UBS | Target | Target: $12 | Target: $7 |
| Mar 2, 2026 | Cantor Fitzgerald | Target | Target: — | Target: $8 |
| Jan 5, 2026 | Piper Sandler | Upgrade | Target: $4 | Target: $9 |
| Jan 5, 2026 | Raymond James | Target | Target: — | Target: $9 |
| Dec 22, 2025 | UBS | Target | Target: — | Target: $12 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $79.8M · Total debt $42.0M · Total assets $104.9M · Shareholders' equity $52.9M
- Revenue
- $23.4M
- Operating income
- −$3.9M
- Net income
- −$4.4M
No dividends on record.
| Institutions | ≈ 40.75% | 22.45M shares | |
|---|---|---|---|
| 115 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 47.07% | 25.93M shares | |
| 20 holders · as of Aug 18, 2026 | |||
| Other | ≈ 12.18% | 6.71M shares | |
| remainder | |||
55.09M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Staffan Encrantz1Insiderdirector, 10 percent owner | 12.95% | 6.73M | filed Jun 11, 2026 |
Paul Badawi2Insiderdirector, 10 percent owner, officer: President and CEO | 9.94% | 5.40M | filed Jul 6, 2026 |
Long Focus Capital Management, LLCInstitution | 6.98% | 3.84M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 5.60% | 3.08M | as of Jun 30, 2026 |
UBS Group AG directly and on behalf of certain subsidiaries.Institution | 5.23% | 2.88M | filed Feb 7, 2024 |
- Staffan Encrantz's transaction reports restate only vehicles that traded; the 2025 ownership statement (6.73M) plus the 404.8K net shares acquired since is used instead.
- Paul Badawi's own ownership statement (13G, Feb 14, 2022) plus the 77.3K net shares acquired since reports fewer shares than the transaction reports; the statement is used.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 1, 2026 | Paul Badawi | director, 10 percent owner, officer: President and CEO | −28,684 | $5.42 |
| Jul 2, 2026 | Alison Bauerlein | officer: Chief Operating Officer | −24,184 | $5.36 |
| Jul 1, 2026 | Brenton Taylor | officer: EVP, Operations & R&D | −2,829 | $5.42 |
| Jul 6, 2026 | David Badawi | director, officer: Chief Technology Officer | −7,418 | $5.51 |
| Jul 2, 2026 | James Rodberg | officer: Chief Financial Officer | −6,902 | $5.36 |
- Glaukos
MIGS stents and sustained glaucoma implants
- Alcon
Hydrus and iLux span glaucoma and dry-eye procedures
- AbbVie
XEN, Durysta, and Restasis challenge eye-care adoption
- National Vision
Canaloplasty devices closest to OMNI's implant-free lane
- Johnson & Johnson
LipiFlow is a direct MGD procedure alternative
- Bausch + Lomb
Prescription dry-eye drugs pressure TearCare's alternatives
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Sight Sciences | $8.59 | −0.06% | $461.9M | — | — | 5.5 | +19.6% |
| Glaukos | $159.86 | −0.05% | $9.53B | — | 1,248.5 | 15.5 | +49.5% |
| Alcon | $65.59 | 0.00% | $31.64B | 49.9 | 17.3 | 2.9 | +7.5% |
| AbbVie | $265.04 | −0.09% | $467.37B | 74.5 | 17.5 | 7.3 | +10.2% |
| National Vision | $16.60 | 0.00% | $1.32B | 26.9 | 15.3 | 0.6 | +2.6% |
| Johnson & Johnson | $269.61 | +0.12% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| Bausch + Lomb | $17.32 | −0.06% | $6.00B | — | 17.4 | 1.1 | +9.1% |
| Median | 40.6 | 17.4 | 4.8 | +8.3% |